SCHEMBL13802423

SCHEMBL13802423

Cc1ccccc1Cn1c(C)c(CC(=O)O)c2ccccc21

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 7/20 0.61
THRB P10828 2/20 0.57
THRA P10827 1/20 0.57
PLA2G2A P14555 3/20 0.55
KDM4E B2RXH2 1/20 0.52
MEN1 O00255 1/20 0.52
ALDH1A1 P00352 1/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52
KMT2A Q03164 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
PLA2G1B P04054 1/20 0.52
ABCB1 P08183 1/20 0.49
PTGS1 P23219 1/20 0.49
PTGS2 P35354 1/20 0.49
GFER P55789 1/20 0.49
PTGES O14684 1/20 0.47
ALOX5 P09917 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20769712 0.87 PTGDR2 (0.69) PTGDR2THRBTHRAPLA2G2AMEN1
SCHEMBL1939990 0.81 PTGDR2 (0.79) PTGDR2
SCHEMBL13802422 0.81 PTGDR2 (0.76) PTGDR2THRBTHRAPLA2G2AKDM4E
SCHEMBL4209387 0.80 PTGDR2 (0.74) PTGDR2THRBTHRAPLA2G2AKDM4E
SCHEMBL13802405 0.79 PTGDR2 (0.70) PTGDR2THRBTHRAPLA2G2APLA2G1B
SCHEMBL4211522 0.79 PTGDR2 (0.72) PTGDR2THRBTHRAPLA2G2AKDM4E
SCHEMBL13802427 0.78 THRA (0.65) PTGDR2THRBTHRAPLA2G2APLA2G1B
SCHEMBL4270126 0.77 THRA (0.71) PTGDR2THRBTHRAPLA2G2AKDM4E
SCHEMBL3851112 0.77 ADAM17 (0.44) THRBPLA2G2AKDM4EMEN1ALDH1A1
SCHEMBL3851108 0.77 ADAM17 (0.44) THRBPLA2G2AKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD MYRIAD GENETICS, INCORPORATED (US) 2009-06-18 US disclosed
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD MYRIAD GENETICS, INCORPORATED (US) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD APP, PSEN2, PSEN1 PTGDR2 2287/4885THRB 3290/4885THRA 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.